Biotech News
Related news
RVMDRevolution Medicines2026-06-23 12:00 EST
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
RVMDRevolution Medicines2026-05-31 12:06 EST
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
LYELLyell Immunopharma2026-06-04 20:05 EST
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
IDYAIDEAYA Biosciences2026-06-15 10:00 EST
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
ELVNEnliven Therapeutics2026-06-03 20:05 EST
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
CLDXCelldex Therapeutics2026-06-14 09:15 EST
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
KYMRKymera2026-06-09 11:00 EST
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
LEGNLegend Biotech Corporation2026-06-15 12:00 EST
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Vaccinex
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
Recent company news
VCNXVaccinex2026-04-30 00:05 EST
Vaccinex Reports 2025 Annual Financial Results
VCNXVaccinex2025-12-23 13:01 EST
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
VCNXVaccinex2025-05-27 12:45 EST
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
VCNXVaccinex2025-04-21 12:45 EST
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
VCNXVaccinex2025-03-07 22:15 EST
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Stock data
- Close
- 0.78 USD
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States